Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30053951 | 0.84 | GPR3 (0.44) | GPR3NPC1RAB9AGMNNUSP2 | |
| SCHEMBL462815 | 0.84 | GPR3 (0.44) | GPR3NPC1RAB9AGMNNUSP2 | |
| SCHEMBL29546263 | 0.81 | NR4A1 (0.56) | GPR3NPC1RAB9AGMNNUSP2 | |
| SCHEMBL442684 | 0.81 | NR4A1 (0.56) | GPR3NPC1RAB9AGMNNUSP2 | |
| SCHEMBL22714098 | 0.81 | GPR3 (0.48) | GPR3NPC1RAB9AGMNNUSP2 | |
| Hydrochloric Acid SCHEMBL9526864 | 0.79 | NR4A1 (0.54) | GPR3NPC1RAB9AGMNNUSP2 | |
| SCHEMBL30459994 | 0.78 | GPR3 (0.46) | GPR3NPC1RAB9AGMNNUSP2 | |
| SCHEMBL30628388 | 0.78 | GPR3 (0.46) | GPR3NPC1RAB9AGMNNUSP2 | |
| SCHEMBL17420607 | 0.78 | GPR3 (0.46) | GPR3NPC1RAB9AGMNNUSP2 | |
| SCHEMBL1275899 | 0.78 | GPR3 (0.46) | GPR3NPC1RAB9AGMNNUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3636643-A1 | NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2019-02-21 | — | — | US | disclosed |
| US-10106501-B2 | Nuclear receptor modulators | ABBVIE INC. (US) | 2018-10-23 | — | — | US | disclosed |
| EP-3307734-A1 | NUCLEAR RECEPTOR MODULATORS | AbbVie Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2016200851-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2012028676-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| CN-101505762-A | Orally active purinyl inhibitors of heat shock protein 90 | CONFORMA THERAPEUTICS CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-1962863-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | Conforma Therapeutics Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362370-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | GPR3 149/4885NPC1 346/4885RAB9A 4439/4885 |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | GPR3 3615/4885NPC1 1532/4885RAB9A 2657/4885 |
| US-10106501-B2 | Nuclear receptor modulators | NR1I2, NR1H2, NR5A2 | GPR3 149/4885NPC1 346/4885RAB9A 4439/4885 |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | GPR3 149/4885NPC1 346/4885RAB9A 4439/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | GPR3 149/4885NPC1 346/4885RAB9A 4439/4885 |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | GPR3 149/4885NPC1 346/4885RAB9A 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.